Pyrotinib and Trastuzumab Combined With Dalpiciclib Versus Combined With Docetaxel in Advanced HER2-Positive Breast Cancer
Clinical trial NCT07615751 · RECRUITING
Trial details
- NCT number
- NCT07615751
- Sponsor
- Fudan University
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-02-12
- Primary completion
- 2028-12-30
- Enrollment
- 502
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.